vs
Side-by-side financial comparison of FIRSTSUN CAPITAL BANCORP (FSUN) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $110.0M, roughly 1.1× FIRSTSUN CAPITAL BANCORP). FIRSTSUN CAPITAL BANCORP runs the higher net margin — 19.6% vs 3.3%, a 16.3% gap on every dollar of revenue. Over the past eight quarters, FIRSTSUN CAPITAL BANCORP's revenue compounded faster (6.9% CAGR vs 5.6%).
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
FSUN vs NATR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $110.0M | $123.8M |
| Net Profit | $21.6M | $4.1M |
| Gross Margin | — | 72.5% |
| Operating Margin | — | 4.3% |
| Net Margin | 19.6% | 3.3% |
| Revenue YoY | — | 4.7% |
| Net Profit YoY | -8.4% | 1379.4% |
| EPS (diluted) | $0.76 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.0M | — | ||
| Q4 25 | $110.2M | $123.8M | ||
| Q3 25 | $107.3M | $128.3M | ||
| Q2 25 | $105.6M | $114.8M | ||
| Q1 25 | $96.2M | $113.2M | ||
| Q4 24 | $98.7M | $118.2M | ||
| Q3 24 | $98.2M | $114.6M | ||
| Q2 24 | $96.2M | $110.6M |
| Q1 26 | $21.6M | — | ||
| Q4 25 | $24.8M | $4.1M | ||
| Q3 25 | $23.2M | $5.3M | ||
| Q2 25 | $26.4M | $5.3M | ||
| Q1 25 | $23.6M | $4.7M | ||
| Q4 24 | $16.4M | $-321.0K | ||
| Q3 24 | $22.4M | $4.3M | ||
| Q2 24 | $24.6M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 73.3% | ||
| Q2 25 | — | 71.7% | ||
| Q1 25 | — | 72.1% | ||
| Q4 24 | — | 72.0% | ||
| Q3 24 | — | 71.3% | ||
| Q2 24 | — | 71.4% |
| Q1 26 | — | — | ||
| Q4 25 | 29.0% | 4.3% | ||
| Q3 25 | 26.4% | 7.0% | ||
| Q2 25 | 31.2% | 3.7% | ||
| Q1 25 | 30.9% | 5.4% | ||
| Q4 24 | 20.4% | 3.8% | ||
| Q3 24 | 29.1% | 4.6% | ||
| Q2 24 | 32.3% | 5.1% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 22.5% | 3.3% | ||
| Q3 25 | 21.6% | 4.2% | ||
| Q2 25 | 25.0% | 4.6% | ||
| Q1 25 | 24.5% | 4.2% | ||
| Q4 24 | 16.6% | -0.3% | ||
| Q3 24 | 22.8% | 3.8% | ||
| Q2 24 | 25.5% | 1.2% |
| Q1 26 | $0.76 | — | ||
| Q4 25 | $0.89 | $0.23 | ||
| Q3 25 | $0.82 | $0.30 | ||
| Q2 25 | $0.93 | $0.28 | ||
| Q1 25 | $0.83 | $0.25 | ||
| Q4 24 | $0.57 | $-0.02 | ||
| Q3 24 | $0.79 | $0.23 | ||
| Q2 24 | $0.88 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $413.7M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $161.6M |
| Total Assets | $8.6B | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $413.7M | — | ||
| Q4 25 | $652.6M | $93.9M | ||
| Q3 25 | $659.9M | $95.6M | ||
| Q2 25 | $785.1M | $81.3M | ||
| Q1 25 | $621.4M | $86.5M | ||
| Q4 24 | $615.9M | $84.7M | ||
| Q3 24 | $573.7M | $78.7M | ||
| Q2 24 | $535.8M | $68.7M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $161.6M | ||
| Q3 25 | $1.1B | $166.7M | ||
| Q2 25 | $1.1B | $163.7M | ||
| Q1 25 | $1.1B | $167.1M | ||
| Q4 24 | $1.0B | $161.0M | ||
| Q3 24 | $1.0B | $162.6M | ||
| Q2 24 | $996.6M | $156.4M |
| Q1 26 | $8.6B | — | ||
| Q4 25 | $8.5B | $261.1M | ||
| Q3 25 | $8.5B | $264.8M | ||
| Q2 25 | $8.4B | $254.9M | ||
| Q1 25 | $8.2B | $252.7M | ||
| Q4 24 | $8.1B | $240.9M | ||
| Q3 24 | $8.1B | $245.3M | ||
| Q2 24 | $8.0B | $235.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $9.9M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $111.5M | $9.9M | ||
| Q3 25 | $49.4M | $18.5M | ||
| Q2 25 | $15.0M | $4.3M | ||
| Q1 25 | $26.4M | $2.6M | ||
| Q4 24 | $101.1M | $12.2M | ||
| Q3 24 | $48.1M | $9.6M | ||
| Q2 24 | $20.9M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | $104.0M | $7.6M | ||
| Q3 25 | $47.6M | $16.8M | ||
| Q2 25 | $13.0M | $3.0M | ||
| Q1 25 | $24.3M | $1.5M | ||
| Q4 24 | $95.7M | $10.0M | ||
| Q3 24 | $47.1M | $7.9M | ||
| Q2 24 | $19.9M | $-2.0M |
| Q1 26 | — | — | ||
| Q4 25 | 94.3% | 6.1% | ||
| Q3 25 | 44.4% | 13.1% | ||
| Q2 25 | 12.3% | 2.6% | ||
| Q1 25 | 25.3% | 1.3% | ||
| Q4 24 | 97.0% | 8.5% | ||
| Q3 24 | 47.9% | 6.9% | ||
| Q2 24 | 20.6% | -1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 1.9% | ||
| Q3 25 | 1.6% | 1.3% | ||
| Q2 25 | 1.9% | 1.2% | ||
| Q1 25 | 2.1% | 1.0% | ||
| Q4 24 | 5.5% | 1.9% | ||
| Q3 24 | 1.1% | 1.5% | ||
| Q2 24 | 1.1% | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.49× | 2.41× | ||
| Q3 25 | 2.13× | 3.46× | ||
| Q2 25 | 0.57× | 0.81× | ||
| Q1 25 | 1.12× | 0.55× | ||
| Q4 24 | 6.18× | — | ||
| Q3 24 | 2.15× | 2.21× | ||
| Q2 24 | 0.85× | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
